<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00848055</url>
  </required_header>
  <id_info>
    <org_study_id>1240.1</org_study_id>
    <nct_id>NCT00848055</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Single Rising, Open-label Doses of AbGn-168 Administered by Intravenous Infusion (1 Mcg/kg, 5 Mcg/kg, 25 Mcg/kg, 125 Mcg/kg, 625 Mcg/kg, 3 mg/kg, or 10 mg/kg) or Subcutaneous Injection (625 Mcg/kg) to Patients With Chronic Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The general aim of the trial is to determine the safety, tolerability and pharmacologic
      profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously
      to patients with chronic plaque psoriasis
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measurements including physical examination, vital signs, ECG, clinical laboratory tests, and adverse events</measure>
    <time_frame>Baseline, on treatment,and at end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic and pharmacodynamic endpoints including Cmax, tmax, AUC, t1/2, CL and Vss, target lesion assessment and skin biopsy</measure>
    <time_frame>Baseline and on treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 5</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 8</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AbGn168 cohort 8</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 intravenous infusion</intervention_name>
    <description>single dose intravenous infusion</description>
    <arm_group_label>arm 7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AbGn168 subcutaneous injection</intervention_name>
    <description>single dose subcutaneous injection</description>
    <arm_group_label>arm 8</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        Patients with chronic plaque psoriasis covering at least 3% of body surface area. Female
        subjects must be postmenopausal or surgically sterilized.

        Exclusion criteria:

        Recent use of biologic agents, oral psoriasis medications or phototherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1240.1.05 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.06 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.04 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.02 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.01 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.03 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1240.1.7 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2009</study_first_posted>
  <last_update_submitted>October 31, 2013</last_update_submitted>
  <last_update_submitted_qc>October 31, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2013</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

